ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

REVEALING THE VARIOUS CAUSES OF MANDIBULAR FRACTURES

AUTHORS:

Dr. Kanwal Iftikhar, Dr. Maryam Zafar, Dr. Noveera Javed

ABSTRACT:

Objective: To evaluate the effectiveness and adverse reactions of intravenous magnesium to oral nifedipine for severe tocolysis of preterm labor. Methods: A multicenter random trial was carried out. Patients specifically in active preterm labor who had been at 24 to 33 weeks and 6 days of pregnancy happened to be at random designated to obtain magnesium sulfate or nifedipine. The elementary results were the arrest of preterm labor, characterized as prevention of delivery for 48 hours with uterine quiescence. Results: One hundred ninety-two patients had been enlisted. Additional patients designated to magnesium sulfate attained the major result (87% compared with 72%, according to the value of P .01). There had been no distinctions in delivery just in 48 hours (7.6% magnesium sulfate when compared with 8.0% nifedipine, with the value of P .92), gestational age at delivery (35.8 reviewed with 36.0 weeks, P .61), birth earlier 37 and 32 weeks (57% reviewed along with 57%, P .97, and 11% reviewed with 8%, P .39), and episodes of frequent preterm labor. Mild and serious maternal unfavorable effects were considerably more continual with magnesium sulfate. Birth weight, birth weight less than 2,500 g, and neonatal morbidities had been matching in between groups, however, infants in the magnesium sulfate group spent a bit longer in the neonatal intensive care unit (8.8 17.7 in comparison with 4.2 8.2 days, P .007). Conclusion: Patients that obtained magnesium sulfate obtained the elementary result more frequently. Though, gestational age at delivery, delay of delivery, and neonatal outcomes had been equivalent in between groups. Nifedipine was involved with a lesser number of maternal adverse consequences. Keywords: Preterm labor; Magnesium sulfate; Nifedipine; Tocolysis; Comparison.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.